Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Overview

How likely is it that the drugs in Genital Warts (Condylomata Acuminata) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Genital Warts (Condylomata Acuminata) Overview

Genital warts (condyloma acuminatum) are a sexually transmitted infection caused by the human papillomavirus (HPV) types 6 and 11. It is spread by skin-to-skin contact, usually during sex. The warts present in clusters or separately and can be found in the genital or anal area. Genital warts are typically painless but can cause itching, discomfort, or bleeding. Treatments may include topical medications, cryotherapy (freezing), laser therapy, or surgical removal. Vaccination against certain HPV strains is available and recommended for preventing genital warts and related complications, including cervical cancer in women. Safe sexual practices and regular screenings are essential for prevention and early detection.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for industry benchmarks and drug comparisons.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Reasons to buy

  • Predict the specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions.

What our clients have to say

More Reports

View More Reports